0.00
—
Close of 29 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genex Pharmaceutical
Its shares trade under the ticker GENX. It has been listed since 23 May 2006. In the fiscal year to 31 December 2007, it reported revenue of $3.2m and net income of $342,549. At that date it held total assets of $8.6m and shareholders' equity of $4.7m.
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft, which is considered as a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2006-05-23. Genex was a start-up, Internet-based fulfillment company with offices in Vancouver, British Columbia, Canada. On June 8, 2004, Genex entered into a share purchase agreement with Tianjin Zhongjin Biology Development Co., Ltd. (Zhongjin). On June 17, 2004, the stock purchase made pursuant to the share purchase agreement was consummated and Zhongjin became a wholly owned subsidiary of Genex. Zhongjin engages in the business of producing and distributing Reconstituted Bone Xenograft (RBX), which is considered a medical device that accelerates bone healing. Zhongjin solely markets its medical devices to hospitals in China. Zhongjin distributes its medical devices to more than 500 hospitals in 30 provinces throughout China. Zhongjin also markets its medical devices to medical device customers in China that are not hospitals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 23 May 2006
- Employees
- 86
Leadership
Pay as last reported
- Song FuzhiChairman of the Board, President, Chief Executive Officer, since 2004
- Zhang ShuliChief Financial Officer, Treasurer
- Sufen AiSecretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genex Pharmaceutical Inc has a strong research and development team that constantly innovates in the pharmaceutical industry, allowing them to create cutting-edge products.
- The company has a well-established brand reputation and a loyal customer base, thanks to their consistent delivery of high-quality pharmaceutical products.
Weaknesses
- Genex Pharmaceutical Inc operates in a highly competitive market, where other pharmaceutical companies constantly strive to gain market share, which poses a challenge to the company's growth.
- The company heavily relies on a few key products, making their revenue stream vulnerable to any issues that might arise with these products.
Opportunities
- Genex Pharmaceutical Inc can capitalize on the growing demand for personalized medicine by developing and offering customized pharmaceutical solutions.
- Expanding into emerging markets, such as Asia and Latin America, could provide Genex Pharmaceutical Inc with new growth opportunities.
Threats
- Increasing regulations and strict approval processes in the pharmaceutical industry can pose challenges and delays in launching new products.
- The rising cost of research and development, coupled with pricing pressures from payers and healthcare systems, can impact Genex Pharmaceutical Inc's profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.